Riluzole therapy in Huntington's disease (HD)
Identifieur interne : 007949 ( Main/Merge ); précédent : 007948; suivant : 007950Riluzole therapy in Huntington's disease (HD)
Auteurs : H. Diana Rosas [États-Unis] ; Walter J. Koroshetz [États-Unis] ; Bruce G. Jenkins [États-Unis] ; Y. Iris Chen ; Douglas L. Hayden [États-Unis] ; M. Flint Beal [États-Unis] ; Merit E. Cudkowicz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-03.
English descriptors
- KwdEn :
Abstract
We conducted a 6‐week open‐label trial of riluzole (50 mg twice a day) in eight subjects with Huntington's disease. Subjects were evaluated before riluzole treatment, on treatment, and off treatment with the chorea, dystonia, and total functional capacity (TFC) scores from the Unified Huntington's Disease Rating Scale and magnetic resonance spectroscopy measurements of occipital cortex and basal ganglia lactate levels. Adverse events and safety blood and urine tests were assessed throughout the study. All subjects completed the study and riluzole was well tolerated. The age was 45 ± 10.2 years (mean ± standard deviation) and the disease duration was 6.1 ± 4.1 years. The chorea rating score improved by 35% on treatment (p = 0.013) and worsened after discontinuation of treatment (p = 0.026). There were no significant treatment effects on the dystonia or TFC scores. The baseline occipital and basal ganglia lactate levels were elevated in all subjects; there was a trend toward lower lactate/creatine ratios during riluzole treatment in the basal ganglia spectra but not in occipital cortex spectra. Additional clinical studies of riluzole for both symptomatic and neuroprotective benefit in Huntington's disease are warranted.
Url:
DOI: 10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F81
- to stream Istex, to step Curation: 001F81
- to stream Istex, to step Checkpoint: 003417
Links to Exploration step
ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole therapy in Huntington's disease (HD)</title><author><name sortKey="Rosas, H Diana" sort="Rosas, H Diana" uniqKey="Rosas H" first="H. Diana" last="Rosas">H. Diana Rosas</name></author><author><name sortKey="Koroshetz, Walter J" sort="Koroshetz, Walter J" uniqKey="Koroshetz W" first="Walter J." last="Koroshetz">Walter J. Koroshetz</name></author><author><name sortKey="Jenkins, Bruce G" sort="Jenkins, Bruce G" uniqKey="Jenkins B" first="Bruce G." last="Jenkins">Bruce G. Jenkins</name></author><author><name sortKey="Chen, Y Iris" sort="Chen, Y Iris" uniqKey="Chen Y" first="Y. Iris" last="Chen">Y. Iris Chen</name></author><author><name sortKey="Hayden, Douglas L" sort="Hayden, Douglas L" uniqKey="Hayden D" first="Douglas L." last="Hayden">Douglas L. Hayden</name></author><author><name sortKey="Beal, M Flint" sort="Beal, M Flint" uniqKey="Beal M" first="M. Flint" last="Beal">M. Flint Beal</name></author><author><name sortKey="Cudkowicz, Merit E" sort="Cudkowicz, Merit E" uniqKey="Cudkowicz M" first="Merit E." last="Cudkowicz">Merit E. Cudkowicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q</idno><idno type="url">https://api.istex.fr/document/7A70222DCD70873629959102D42BFCB7987DC0C0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F81</idno><idno type="wicri:Area/Istex/Curation">001F81</idno><idno type="wicri:Area/Istex/Checkpoint">003417</idno><idno type="wicri:doubleKey">0885-3185:1999:Rosas H:riluzole:therapy:in</idno><idno type="wicri:Area/Main/Merge">007949</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Riluzole therapy in Huntington's disease (HD)</title><author><name sortKey="Rosas, H Diana" sort="Rosas, H Diana" uniqKey="Rosas H" first="H. Diana" last="Rosas">H. Diana Rosas</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation><affiliation><wicri:noCountry code="subField">Massachusetts;</wicri:noCountry></affiliation></author><author><name sortKey="Koroshetz, Walter J" sort="Koroshetz, Walter J" uniqKey="Koroshetz W" first="Walter J." last="Koroshetz">Walter J. Koroshetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Jenkins, Bruce G" sort="Jenkins, Bruce G" uniqKey="Jenkins B" first="Bruce G." last="Jenkins">Bruce G. Jenkins</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Chen, Y Iris" sort="Chen, Y Iris" uniqKey="Chen Y" first="Y. Iris" last="Chen">Y. Iris Chen</name><affiliation><wicri:noCountry code="subField">Massachusetts;</wicri:noCountry></affiliation></author><author><name sortKey="Hayden, Douglas L" sort="Hayden, Douglas L" uniqKey="Hayden D" first="Douglas L." last="Hayden">Douglas L. Hayden</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>General Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Beal, M Flint" sort="Beal, M Flint" uniqKey="Beal M" first="M. Flint" last="Beal">M. Flint Beal</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Cudkowicz, Merit E" sort="Cudkowicz, Merit E" uniqKey="Cudkowicz M" first="Merit E." last="Cudkowicz">Merit E. Cudkowicz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-03">1999-03</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="326">326</biblScope><biblScope unit="page" to="330">330</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7A70222DCD70873629959102D42BFCB7987DC0C0</idno><idno type="DOI">10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q</idno><idno type="ArticleID">MDS1019</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chorea</term><term>Energy metabolism</term><term>Huntington's disease</term><term>Lactate</term><term>Magnetic resonance spectroscopy</term><term>Riluzole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a 6‐week open‐label trial of riluzole (50 mg twice a day) in eight subjects with Huntington's disease. Subjects were evaluated before riluzole treatment, on treatment, and off treatment with the chorea, dystonia, and total functional capacity (TFC) scores from the Unified Huntington's Disease Rating Scale and magnetic resonance spectroscopy measurements of occipital cortex and basal ganglia lactate levels. Adverse events and safety blood and urine tests were assessed throughout the study. All subjects completed the study and riluzole was well tolerated. The age was 45 ± 10.2 years (mean ± standard deviation) and the disease duration was 6.1 ± 4.1 years. The chorea rating score improved by 35% on treatment (p = 0.013) and worsened after discontinuation of treatment (p = 0.026). There were no significant treatment effects on the dystonia or TFC scores. The baseline occipital and basal ganglia lactate levels were elevated in all subjects; there was a trend toward lower lactate/creatine ratios during riluzole treatment in the basal ganglia spectra but not in occipital cortex spectra. Additional clinical studies of riluzole for both symptomatic and neuroprotective benefit in Huntington's disease are warranted.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007949 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007949 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0
|texte= Riluzole therapy in Huntington's disease (HD)
}}
| This area was generated with Dilib version V0.6.23. |  |